DOCSLIB.ORG

China Everbright Limited to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
China Everbright Limited to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx China Everbright Limited to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx 22 May, 2015 – A consortium (the “Consortium”) consisting of China Everbright Limited (“CEL”, Stock Code: 165.HK)’s health care fund, Fosun Pharma, HOPU Investments and WuXi PharmaTech announced that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. (“Ambrx”). The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions. Ambrx is a clinical-stage biotechnology company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates. Its proprietary technology platforms enable attachment of pharmaceutically active molecules to specific sites within proteins more precisely than prior generations of bio-conjugates. Ambrx has developed a pipeline of novel product candidates that include antibody drug conjugates, or ADCs, bi- and multi-specific drug conjugates and long-acting therapeutic proteins. ADCs are expected to be one of the most important areas of monoclonal antibody development, especially in targeted therapies for oncology, an area where Ambrx has a strong pipeline. Ambrx’s most advanced internally developed product is a site-specific ADC targeting Her2-positive breast cancer. In addition to its pipeline, Ambrx collaborates with leading pharmaceutical companies, including Bristol-Myers Squibb, Merck, and Eli Lilly, on a series of projects including ADCs-oncology, bi-specific drug conjugates and long-acting therapeutic proteins. Ambrx’s most advanced collaboration product candidate in human health is ARX618, a long-acting fibroblast growth factor 21 for type 2 diabetes, for which collaboration partner Bristol-Myers Squibb is conducting Phase 2 clinical trials in the United States. To date, collaborations have provided Ambrx with over a hundred million US dollars in funding. Mr. Chen Shuang, CEO of CEL said, “This collaboration brings together resources from leading China-based pharmaceutical enterprises and leading U.S.-based innovators in biologics development, together with the financial resources and networks from CEL, which will result in a great synergy. Upon completion of the acquisition, Ambrx will obtain quality resources from its Chinese partners, so as to further advance the technical innovation of their research center based in the U.S., and to establish a global product development center based in China. We believe that, with the support of the cooperation partners, Ambrx’s business will expand rapidly in China.” – Ends – About CEL China Everbright Limited (“CEL”, stock code: 165.HK) has woven huge cross-border social and business networks in Hong Kong and the Mainland. CEL, being a member of China Everbright Group, is a diversified financial services enterprise operating in Hong Kong and Mainland China. It is the second largest shareholder of Everbright Securities (stock code: 601788.SH) and third largest shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK) in the Mainland. 1 / 3 中國光大控股有限公司 China Everbright Limited 香港夏愨道 16 號遠東金融中心 46 樓 46/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. 電話 Tel: (852) 2528 9882 傳真 Fax: (852) 2529 0177 網頁 Website: www.everbright165.com Established in 1997 at Hong Kong, CEL persistently pursues its “Macro Asset Management” strategy, with specific focuses being placed on fund management and investment businesses, namely Primary Market Investment, Secondary Market Investment and Structured Financing and Investment. Moreover, being a substantial shareholder of China Aircraft Leasing Company Limited, CEL is actively developing aircraft leasing business in China and emerging markets. In addition, by leveraging the advantages in cross-border fee-based business of an associate, Everbright Securities, CEL also participates in the development of investment banking (corporate financing) and brokerage services (wealth management) businesses in Hong Kong. Over the past years, CEL has developed solid bases in various sector markets. It manages series of private equity funds, venture capital funds, sector focus funds and hedge funds as operated via an international management platform, and provides overseas investors with opportunities to explore and invest in companies with fast growing potential in the Mainland China. On the other hand, CEL also seeks investment opportunities from overseas and provides diversified financial services for its clients in Mainland China. As of 31 December 2014, CEL’s asset under management reached over HK$50.3 billion, with a total of 24 funds. Through upholding the philosophy of “Making Wealth Simple”, CEL leverages on its own substantial financial strength, as well as the position and influence of China Everbright Group and its affiliated companies in the financial industry in China, and has successfully built huge cross-border social and business networks in Hong Kong and the Mainland, and established a reputable image in the market. For more information on CEL, please visit www.everbright165.com CEL Healthcare Fund focus on leading healthcare/life science companies with a defendable competitive position, an excellent prospect of expandable platform, and a good fit with the great resources and market potential that China has to offer. The CEL team has extensive experiences and network in the healthcare sector in China and US. About Fosun Pharma Shanghai Fosun Pharmaceutical (“Fosun Pharma”), a leading healthcare company in China，which was established in 1994 ,has been listed on the Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited since 2012 ( stock code: 600196-SH,02196-HK). Fosun Pharma strategically covers important segments of the healthcare industry value-chain, including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices. Fosun Pharma maintains a National Recognized Enterprise Technology Centre and a highly capable international R&D team, focusing on innovation and research in therapeutic areas including cardiovascular system, metabolism and alimentary system, central nervous system, blood system, anti-infection and anti-tumor. With its commitment to innovation for good health and creating a better future, Fosun Pharma will continue insisting on the strategic development approach of “Organic Growth, Coupled with M&A and Integration”. The Company strives to be one of the first-class enterprises in the global healthcare market. Click here for more information: www.fosunpharma.com. About WuXi PharmaTech WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information on WuXi’s biologics services, please visit: www.wuxiapptec.com. 2 / 3 中國光大控股有限公司 China Everbright Limited 香港夏愨道 16 號遠東金融中心 46 樓 46/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. 電話 Tel: (852) 2528 9882 傳真 Fax: (852) 2529 0177 網頁 Website: www.everbright165.com About HOPU Investments HOPU Investments is a private equity firm focusing on China-related investment opportunities. With offices located in Beijing, Hong Kong, and Singapore, HOPU's Team has unique expertise in investment, financing and capital market, as well as diverse experiences working with State Owned Enterprises and private entrepreneurs. HOPU's key investment focus is to create, develop and pursue investment opportunities that are driven by China's ongoing economic reforms and developments, in particular in healthcare, technology, consumer, energy, mining, agriculture and financial services sectors. 3 / 3 中國光大控股有限公司 China Everbright Limited 香港夏愨道 16 號遠東金融中心 46 樓 46/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. 電話 Tel: (852) 2528 9882 傳真 Fax: (852) 2529 0177 網頁 Website: www.everbright165.com .
Load more

Recommended publications
  • A Chinese Pharmaceutical Startup Acquires an American Firm to “Go Global”
    Paulson Papers on Investment Case Study Series A Chinese Pharmaceutical Startup Acquires an American Firm to “Go Global” June 2016 Paulson Papers on Investment Case Study Series Preface or decades, bilateral investment manufacturing—to identify tangible has flowed predominantly from the opportunities, examine constraints and FUnited States to China. But Chinese obstacles, and ultimately fashion sensible investments in the United States have investment models. expanded considerably in recent years, and this proliferation of direct investments Most of the case studies in this Investment has, in turn, sparked new debates about series look ahead. For example, our the future of US-China economic relations. agribusiness papers examine trends in the global food system and specific US and Unlike bond holdings, which can be Chinese comparative advantages. They bought or sold through a quick paper propose prospective investment models. transaction, direct investments involve people, plants, and other assets. They are But even as we look ahead, we also a vote of confidence in another country’s aim to look backward, drawing lessons economic system since they take time from past successes and failures. And both to establish and unwind. that is the purpose of the case studies, as distinct from the other papers in this The Paulson Papers on Investment aim series. Some Chinese investments in to look at the underlying economics— the United States have succeeded. They and politics—of these cross-border created or saved jobs, or have proved investments between the United States beneficial in other ways. Other Chinese and China. investments have failed: revenue sank, companies shed jobs, and, in some Many observers debate the economic, cases, businesses closed.
    [Show full text]
  • Annual Report
    2020 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) Annual Report Profit Attributable to Owners of the Parent RMB 8,017.9 million Innovation & Win The year 2020 might be the most challenging year for Fosun, yet it was also the best year. After the pandemic, we continue with the “wartime mechanism” and maintain the fighting spirit that we have developed during the global combat against COVID-19. This has resulted in our resilient business performance throughout the year. The pandemic has also allowed us to refine further our capabilities of the Company accumulated over the years for “Industry Operations + Industrial Investment”, FC2M model, globalization and technology innovation. Fosun has thus evolved and become even stronger. The theme of Fosun’s annual report this year is “Innovation & Win”. “Innovation” means Fosun always attaches great importance to innovation. We recognize that we can create world-class products only by increasing investment in innovation and R&D. It is also because of our investment in technology innovation in various industries over the years, as well as leveraging on Fosun’s diversified and globalized business portfolio, the development model of “Industry Operations + Industrial Investment”, and the “wartime” mode that it has upkept since the battle against the pandemic, that together effectively defended the impact brought by the external environment and brought the Group a resilient performance, thereby creating mutually beneficial and win-win situation to all stakeholders. The year 2021 is a new starting point for Fosun’s transformation. Facing the huge opportunities in the industrial internet era, we will continue to create good products and put the operation of customers (C-end) as our top priority to fully unlock the multiplier growth of good products and customer resources in Fosun’s ecosystem.
    [Show full text]
  • Biontech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
    BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine January 25, 2021 COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) is the first COVID-19 vaccine to receive Authorization for Emergency Use in Hong Kong MAINZ, GERMANY, and SHANGHAI, CHINA, January 25, 2021 —BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region of the PRC (“Hong Kong”), the COVID-19 vaccine COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) based on BioNTech’s proprietary mRNA technology has received authorization for emergency use in Hong Kong. The vaccine will be produced in BioNTech’s manufacturing facilities in Germany and supplied to Hong Kong for administration under the Hong Kong SAR Government’s COVID-19 Vaccination Program. “We are excited and encouraged that COMIRNATY® has been authorized to emergency use in Hong Kong. This is an important milestone in the joint efforts of BioNTech and Fosun Pharma to achieve vaccine accessibility globally. We will continue working closely with BioNTech to complete the ongoing clinical trial and marketing registration in Greater China,” Wu Yifang, Chairman and CEO of Fosun Pharma said. “We will also cooperate closely with HKSAR regarding vaccination deployment plan to ensure that Hong Kong citizens can receive a well-tolerated and effective mRNA COVID-19 vaccine as soon as possible in order to protect the health of millions of households.” On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to work jointly on the development and commercialization of a COVID-19 vaccine product in Greater China based on BioNTech’s proprietary mRNA technology platform.
    [Show full text]
  • Pacer CSOP FTSE China A50 ETF Schedule of Investments July 31, 2020 (Unaudited) Shares Value COMMON STOCKS - 98.0% Agriculture - 1.6% Muyuan Foodstuff Co Ltd
    Page 1 of 4 Pacer CSOP FTSE China A50 ETF Schedule of Investments July 31, 2020 (Unaudited) Shares Value COMMON STOCKS - 98.0% Agriculture - 1.6% Muyuan Foodstuff Co Ltd. - Class A 9,230 $ 120,977 Wens Foodstuffs Group Co Ltd. - Class A 4,660 15,857 136,834 Auto Manufacturers - 0.7% SAIC Motor Corp Ltd. - Class A 24,600 64,077 Banks - 23.7% Agricultural Bank of China Ltd. - Class H 352,300 163,039 Bank of China Ltd. - Class H 193,900 92,512 Bank of Communications Co Ltd. - Class A 184,100 125,556 China CITIC Bank Corp Ltd. - Class H 24,700 18,261 China Construction Bank Corp. - Class H 81,500 71,464 China Everbright Bank Co Ltd. - Class H 126,400 68,456 China Merchants Bank Co Ltd. - Class A 108,200 539,489 China Minsheng Banking Corp Ltd. - Class A 254,300 201,851 Industrial & Commercial Bank of China Ltd. - Class A 198,400 140,993 Industrial Bank Co Ltd. - Class A 127,400 285,849 Ping An Bank Co Ltd. - Class A 75,000 143,348 Shanghai Pudong Development Bank Co Ltd. - Class A 132,300 196,379 2,047,197 Beverages - 17.9% Jiangsu Yanghe Brewery Joint-Stock Co Ltd. - Class A 4,000 77,398 Kweichow Moutai Co Ltd. - Class A 4,000 961,777 Wuliangye Yibin Co Ltd. - Class A 16,200 504,835 1,544,010 Building Materials - 1.6% Anhui Conch Cement Co Ltd. - Class H 15,900 139,921 Coal - 0.5% China Shenhua Energy Co Ltd.
    [Show full text]
  • ACAL China Equity Nov17
    ARETE CAPITAL ASIA CHINA: VALUE IN SELECTED NAMES CHINA EQUITY – OVERVIEW CHINA IS TAKING ITS PLACE ON THE WORLD STAGE • China is a critical player in the world economy and is the worlds largest economy on a purchasing power parity basis. • Xi’s position has been reinforced for the next 5yrs and possibly beyond. The new leadership will retain existing key policies with a focus on economic reform and an emphasis on foreign policy. ECONOMIC TRANSFORMATION WELL UNDERWAY • ‘Smokestack’ industries (coal, aluminium and steel) and ‘providing for populace’ businesses (consumer staples and healthcare) are no longer so dominant and being overtaken by manufacturers and service companies. • In many cases, these new ‘service’ industries are redefining business models in established sectors • The China government has selected and carefully encouraged special policies/industries to have Chinese operations challenge the established order – internally and externally INVESTMENT OPPORTUNITIES EXIST • Amongst the many transformations taking place in China, there are numerous great investment opportunities. We do not recommend an index, but selected stocks • Some of these stocks have made significant gains over the last 12months, but there is still more to come 2 CONTENT OVERVIEW ECONOMY Economy Issues Diversification 4 5 6 Equities Remninbi VALUATIONS 7 8 SITUATIONS MiddlePORTFOLIO Class ecosystem ADVISORY 9 10 SELECTED STOCKS Preferred 11 Valuations 13 3 CHINA – ECONOMY CHINA’s ECONOMIC GROWTH REMAINS RESILIENT … • IMF forecasts (not a leading indicator)
    [Show full text]
  • Hang Seng Indexes Announces Index Review Results
    14 August 2020 Hang Seng Indexes Announces Index Review Results Hang Seng Indexes Company Limited (“Hang Seng Indexes”) today announced the results of its review of the Hang Seng Family of Indexes for the quarter ended 30 June 2020. All changes will take effect on 7 September 2020 (Monday). 1. Hang Seng Index The following constituent changes will be made to the Hang Seng Index. The total number of constituents remains unchanged at 50. Inclusion: Code Company 1810 Xiaomi Corporation - W 2269 WuXi Biologics (Cayman) Inc. 9988 Alibaba Group Holding Ltd. - SW Removal: Code Company 83 Sino Land Co. Ltd. 151 Want Want China Holdings Ltd. 1088 China Shenhua Energy Co. Ltd. - H Shares The list of constituents is provided in Appendix 1. The Hang Seng Index Advisory Committee today reviewed the fast expanding innovation and new economy sectors in the Hong Kong capital market and agreed with the proposal from Hang Seng Indexes to conduct a comprehensive study on the composition of the Hang Seng Index. This holistic review will encompass various aspects including, but not limited to, composition and selection of constituents, number of constituents, weightings, and industry and geographical representation, etc. The underlying aim of the study is to ensure the Hang Seng Index continues to serve as the most representative and important benchmark of the Hong Kong stock market. Hang Seng Indexes will report its findings and propose recommendations to the Advisory Committee within six months. The number of constituents of the Hang Seng Index may increase during this period. Hang Seng Indexes Announces Index Review Results /2 2.
    [Show full text]
  • Schedule of Investments (Unaudited) Ishares MSCI Total International Index Fund (Percentages Shown Are Based on Net Assets) September 30, 2020
    Schedule of Investments (unaudited) iShares MSCI Total International Index Fund (Percentages shown are based on Net Assets) September 30, 2020 Mutual Fund Value Total International ex U.S. Index Master Portfolio of Master Investment Portfolio $ 1,034,086,323 Total Investments — 100.4% (Cost: $929,170,670) 1,034,086,323 Liabilities in Excess of Other Assets — (0.4)% (3,643,126) Net Assets — 100.0% $ 1,030,443,197 iShares MSCI Total International Index Fund (the “Fund”) seeks to achieve its investment objective by investing all of its assets in International Tilts Master Portfolio (the “Master Portfolio”), which has the same investment objective and strategies as the Fund. As of September 30, 2020, the value of the investment and the percentage owned by the Fund of the Master Portfolio was $1,034,086,323 and 99.9%, respectively. The Fund records its investment in the Master Portfolio at fair value. The Fund’s investment in the Master Portfolio is valued pursuant to the pricing policies approved by the Board of Directors of the Master Portfolio. Fair Value Hierarchy as of Period End Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows: • Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Fund has the ability to access • Level 2 – Other observable inputs (including, but not limited to, quoted prices
    [Show full text]
  • China Pharmaceuticals China Pharmaceuticals Spring Is in the Air – We Expect a Year of Healthy Growth
    EQUITIES HEALTHCARE March 2017 By: Zhijie Zhao https://www.research.hsbc.com China Pharmaceuticals China China Pharmaceuticals Spring is in the air – we expect a year of healthy growth The policy pain of 2016 starts to ease and the industry’s fundamentals remain robust Multinational companies are reducing their focus on off-patent drugs in China, opening up a range Equities // Healthcare // Equities of opportunities We raise our target prices between 11% and 25%; we prefer Hengrui, Sino Biopharm and CMS, all rated Buy March 2017 March Disclaimer & Disclosures: This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it EQUITIES ● HEALTHCARE March 2017 THIS CONTENT MAY NOT BE DISTRIBUTED TO THE PEOPLE'S REPUBLIC OF CHINA (THE "PRC") (EXCLUDING SPECIAL ADMINISTRATIVE REGIONS OF HONG KONG AND MACAO) The dark clouds are lifting The pain is easing as the risks associated with industry reforms recede We forecast that the net profit growth of our covered companies will average 19% in 2017e and 23% in 2018e, up from 18% in 2016e We raise our target prices by 11-25%; we prefer Hengrui, Sino Biopharm and CMS, all rated Buy Last year we wrote that China’s attempts to improve the healthcare system were proving painful for pharma companies (China Pharmaceuticals – 2016: Painful symptoms, possible remedies, 1 March 2016). We said that, although efforts to cut the cost of healthcare and improve industry standards would make the first half of 2016 difficult, we remained strong believers in China’s pharma story.
    [Show full text]
  • 股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co
    THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agents through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s). Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular. 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) REPORT ON THE USE OF PROCEEDS PREVIOUSLY RAISED AND NOTICE OF EGM A letter from the Board is set out on pages 3 to 5 of this circular. The notice convening the EGM of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* to be held at 1:30 p.m. on Wednesday, 14 July 2021 at Shanghai Film Art Center, No.
    [Show full text]
  • Annual Report 2020 03 Corporate Information
    Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms.
    [Show full text]
  • Hang Seng Indexes Announces Index Review Results of Hang Seng Corporate Sustainability Index Series
    12 August 2016 HANG SENG INDEXES ANNOUNCES INDEX REVIEW RESULTS OF HANG SENG CORPORATE SUSTAINABILITY INDEX SERIES Hang Seng Indexes Company Limited (“Hang Seng Indexes”) today announced the results of its annual review of the Hang Seng Corporate Sustainability Index Series (“Index Series”) for 2016. All changes will be effective on 5 September 2016 (Monday). Shangri-La Asia Ltd (HKEX Stock Code: 69) will be added to the Hang Seng Corporate Sustainability Index (“HSSUS”). Orient Overseas (International) Ltd. (HKEX Stock Code: 316) will be deleted from the HSSUS since the company no longer meets the market capitalisation requirement. The constituent changes and the constituent lists of the five indexes in the Index Series are provided in Appendix 1 and Appendix 2 respectively. The constituent selection of the Index Series includes consideration of the results of the HKQAA Sustainability Rating and Research sustainability assessment, developed and carried out by the Hong Kong Quality Assurance Agency (“HKQAA”), in which the sustainability performance score is measured against the seven core subjects. The HKQAA was appointed by Hang Seng Indexes as its project partner for the Index Series starting from 2014. The three highest-scoring sustainability performers across the Index Series, shown in ascending stock code order, are Hang Seng Bank Ltd. (HKEX Stock Code: 11), Sino Land Co. Ltd. (HKEX Stock Code: 83) and Hong Kong Exchanges and Clearing Ltd. (HKEX Stock Code: 388). more… HANG SENG INDEXES ANNOUNCES INDEX REVIEW RESULTS OF HANG SENG CORPORATE SUSTAINABILITY INDEX SERIES/2 Constituent companies with the highest scores in each of the core subjects across the Index Series are listed below: Core Subjects Company Name (HKEX Stock Code) Community Involvement and HSBC Holdings plc (0005) Development Consumer Issues Orient Overseas (International) Ltd.
    [Show full text]
  • 上海復星醫藥（集團）股份有限公司 Shanghai Fosun Pharmaceutical
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) OVERSEAS REGULATORY ANNOUNCEMENT This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the ‘‘Announcement in Relation to the Signing of License Agreement and Investment Binding Term Sheet by Subsidiaries’’ published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ‘‘Company’’) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail. By order of the Board Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu Chairman Shanghai, the People’s Republic of China 15 March 2020 As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang and Ms. Mu Haining; and the independent non- executive directors of the Company are Mr.
    [Show full text]